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Long tails, short telomeres: Dyskeratosis congenita
Hemanth Tummala and Amanda J. Walne
Dyskeratosis congenita (DC) is an inherited life 
threatening bone marrow failure syndrome [1]. The name 
dyskeratosis comes from the classic triad of clinical 
features nail dystrophy, abnormal skin pigmentation and 
leucoplakia in patients with DC. However the mortality 
in DC is primarily due to bone marrow failure and other 
complications such as pulmonary fibrosis, liver cirrhosis 
and early onset of cancer. DC is genetically heterogeneous 
and harbors constitutional mutations in key genes 
(DKC1, TERC, TERT, NOP10, NHP2, TINF2, TCAB1, 
CTC1, RTEL1 and ACD) that are involved in telomere 
maintenance. In short, telomere maintenance is dependent 
on the catalytic function of telomerase (TERC-RNA 
component of telomerase and TERT-telomerase reverse 
transcriptase), telomerase stability (DKC1-dyskerin, 
NOP10-nucleolar protein 10 homolog and NHP2-
non histone ribonucleoprotein 2 homolog), telomerase 
recruitment (TINF2 -TRF1-interacting nuclear protein 
2 and ACD -adeno cortical dysplasia homologue aka 
TPP1), telomerase trafficking (TCAB1-telomerase cajal 
body 1), telomerase docking (CTC1-conserved telomere 
maintenance component 1) and telomere replication 
(RTEL1-regulator of telomere length 1). DC patients 
carrying mutations in these genes possess critically short 
telomeres and an abnormal DNA damage response, 
causing selective exhaustion of cells in tissues with rapid 
turnover such as the bone marrow [1]. Challenges remain 
to understand the diverse spectrum of disease aetiology 
in DC. In addition the genetic characterisation of clinical 
cases to date accounts only about two thirds of the families 
in our DC registry in London. 
In our latest work published in The Journal of 
Clinical Investigation, we describe the first constitutional 
biallelic mutations in the poly(A)-specific ribonuclease 
(PARN) gene in a subgroup of patients with severe DC 
[2]. These patients have very short telomeres but there 
had been no previous connection reported between PARN 
and telomere biology. PARN is an essential deadenylase 
enzyme that is involved in the control of mRNA stability 
and turnover. Specifically it trims poly(A) tails of mRNA 
to exert translational silencing for a large number of 
genes/transcripts. This is considered to be an important 
function in the regulation of several key cellular pathways 
including nonsense mediated RNA decay (NMD) and the 
DNA damage response. In our study we identified PARN 
deficiency, abnormal p53 regulation, G2/M phase cell 
cycle arrest and cell death upon DNA damage in patient 
cells harboring biallelic PARN mutations. PARN targets 
a discrete set of mRNAs for degradation in non-stress 
conditions, which includes p53 [3]. Upon DNA damage 
PARN binds to the accumulated p53 and other tumour 
suppressor proteins Cstf(50) – cleavage stimulation factor 
and BARD1- BRCA1 associated ring domain protein 1) 
to regulate nuclear deadenylation. Hence PARN activity 
is tightly controlled under different cellular conditions. 
What we have shown [2] is that PARN deficient patient 
cells clearly exhibited a decrease in the stability of several 
key telomere maintenance genes (DKC1, TERF1, RTEL1 
and TERC). However the question still remains as to how 
PARN deficiency specifically leads to telomere attrition in 
these patients with severe DC.
A recent study published in Nature Genetics 
reported heterozygous mutations in PARN associated 
with telomere attrition in patients with idiopathic 
pulmonary fibrosis [5]. This independent study, based 
on a different cohort of patients, also indicates a role for 
PARN in telomere maintenance. The authors of this study 
speculated that haploinsufficiency of PARN may cause 
telomere shortening through down regulation of human 
TERC [4]. However lessons from PARN deadenylase 
targets may imply a direct role in telomere maintenance 
[5]. For example, PARN trims oligoadenylated tails of 
H/ACA-box snoRNAs [5]. As TERC being an H/ACA-
box snoRNA, and known to be oligoadenylated in a small 
fraction of the total TERC pool in human cells [6], it is 
therefore conceivable that PARN deficiency could result in 
accumulation of immature oligoadenylated TERC fraction. 
It is also notable that TERC associates with dyskerin 
(encoded by DKC1), and mutations in DKC1 identified 
in DC patients exhibit low levels of TERC. We observed 
a decrease in DKC1 transcript as well as dyskerin protein 
levels in patient cells with biallelic PARN mutations [2]. 
Furthermore, PARN knockdown studies in a heterologous 
cell system revealed a decrease in DKC1 transcript 
stability after actinomycin D treatment. Hence reduction 
in TERC upon PARN deficiency could be a consequence 
of insufficient dyskerin. PARN deficiency could also 
impact on telomere maintenance via Cajal bodies, sites 
for telomerase trafficking and assembly, since depletion 
of PARN results in reduced size and number of Cajal 
bodies in human cells [5]. Finally a direct association of 
PARN to telomeres is also a possibility as it interacts with 
UPF1 – eukaryotic up-frameshift 1, a key NMD factor that 
localises to telomeres and regulates the polyadenylated 
telomeric repeat containing RNA (TERRA) [7]. 
Editorial
Oncotarget13857www.impactjournals.com/oncotarget
In conclusion, it has been established that PARN 
deadenylation function is important in telomere biology. 
Irrespective of the precise mechanism(s), PARN mutations 
link the basic deadenylation pathway to telomeropathies 
such as idiopathic pulmonary fibrosis and dyskeratosis 
congenita.
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